Jiang Han-Liang, Zhu Hai-Hong, Zhou Lin-Fu, Chen Feng, Chen Zhi
Institute of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, People's Republic of China.
School of Medicine, Zhejiang University, Hangzhou 310031, People's Republic of China.
J Med Microbiol. 2006 Jun;55(Pt 6):715-720. doi: 10.1099/jmm.0.46493-0.
Infection with human papillomavirus (HPV) is the main cause of cervical cancer, the principal cancer in women in most developing countries. Molecular epidemiologic evidence clearly indicates that certain types of HPV are the principal cause of invasive cervical cancer and cervical intraepithelial neoplasia. Comprehensive, high-throughput typing assays for HPV, however, are not currently available. By combining L1 consensus PCR and multiplex hybridization using a Luminex xMAP system-based suspension array, the authors developed a rapid high-throughput assay, the HPV DNA suspension array (HPV-SA), capable of simultaneously typing 26 HPVs, including 18 high-risk HPV genotypes and eight low-risk HPV genotypes. The performance of the HPV-SA applied to 26 synthetic oligonucleotide targets was evaluated. The HPV-SA system perfectly discriminated 18 high-risk HPV targets from eight low-risk HPV targets. To assess the clinical applicability of the assay, the HPV-SA was performed with 133 MY09/MY11 primer set-mediated PCR (MY-PCR)-positive clinical specimens; of the 133 samples, 121 were positive by HPV-SA. Both single and multiple types were easily identified. The authors believe that improvement of the assay may be useful for epidemiological studies, cancer-screening programmes, the monitoring of therapeutic interventions, and the evaluation of the efficacy of HPV vaccine trials.
人乳头瘤病毒(HPV)感染是宫颈癌的主要病因,而宫颈癌是大多数发展中国家女性的主要癌症。分子流行病学证据清楚地表明,某些类型的HPV是浸润性宫颈癌和宫颈上皮内瘤变的主要病因。然而,目前尚无全面、高通量的HPV分型检测方法。通过将L1共识PCR与基于Luminex xMAP系统的悬浮阵列多重杂交相结合,作者开发了一种快速高通量检测方法——HPV DNA悬浮阵列(HPV-SA),能够同时对26种HPV进行分型,包括18种高危HPV基因型和8种低危HPV基因型。评估了HPV-SA应用于26个合成寡核苷酸靶标的性能。HPV-SA系统能完美地区分18个高危HPV靶标和8个低危HPV靶标。为评估该检测方法的临床适用性,对133份经MY09/MY11引物组介导的PCR(MY-PCR)检测呈阳性的临床标本进行了HPV-SA检测;在这133份样本中,121份经HPV-SA检测呈阳性。单一类型和多种类型均易于识别。作者认为,改进该检测方法可能有助于流行病学研究、癌症筛查项目、治疗干预监测以及HPV疫苗试验疗效评估。